News from curetoday.comFollowNews from curetoday.comSee all of curetoday.com news coverage in one place. Discover how curetoday.com’s media bias informs their coverage and compare with thousands of other news outlets.We’ve discovered 100 headlines written by curetoday.com during the past 3 months. We’ve assigned a media bias rating of unknown to curetoday.com. You can read more about our methodology here. curetoday.com’s aggregated factuality score is unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.Follow See all of curetoday.com news coverage in one place. Discover how curetoday.com’s media bias informs their coverage and compare with thousands of other news outlets. We’ve discovered 100 headlines written by curetoday.com during the past 3 months. We’ve assigned a media bias rating of unknown to curetoday.com. You can read more about our methodology here. curetoday.com’s aggregated factuality score is unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check. Information about curetoday.comWhere is curetoday.com located?curetoday.com's WebsiteMedia Bias RatingsDo you diasgree? Edit biasLearn more about Media Bias Ratings.FactualityAverage Factuality Rating: UnknownLearn more about Factuality Ratings.Top curetoday.com NewsBreast Cancer · United StatesFDA expands use of Kisqali to early stage breast cancer patients75% Center coverage: 4 sourcesWomen with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.See the StoryEli Lilly · United StatesLilly gets traditional FDA approval for Retevmo for thyroid cancer (NYSE:LLY)100% Right coverage: 1 sourcesEli Lilly (LLY) has received traditional approval for its drug Retevmo for the treatment of medullary thyroid cancer with a RET mutation. Read more here.See the StoryAstraZeneca · United StatesFDA Expands Approval of Osimertinib in Lung Cancer100% Center coverage: 1 sourcesThe FDA has approved osimertinib (Tagrisso) for locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) following chemoradiotherapy, theSee the StoryLatest News StoriesTopics Most Covered by curetoday.comCancerBreast CancerSportsTechDNACancerBreast CancerSportsSources Covering Similar Topicscancernetwork.comonclive.comtargetedonc.comPharmacy Timesoncnursingnews.comcancernetwork.comonclive.comtargetedonc.comSuggest a sourceLooking for a source we don't already have? Suggest one here.You've scrolled to the bottom of the feed, there are no more stories.Breaking News Topics Related to curetoday.comBreast CancerSwitzerlandCancerUnited States